Letrozol Normon

Letrozole, the active ingredient in Letrozol Normon, is an aromatase inhibitor presented as a tablet for oral use. It reduces estrogen synthesis and is used to treat postmenopausal women with hormone‑receptor positive breast cancer. The medication is administered under medical supervision and forms part of endocrine therapy protocols.

GNH USA supplies Letrozol Normon as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. Our distribution network ensures reliable delivery, regulatory compliance, and support for hospitals, pharmacies, and clinical trial sites across multiple regions.

Letrozole is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer.

Postmenopausal hormone‑receptor positive breast cancer: reduces estrogen levels to inhibit tumor growth. Adjuvant therapy after surgery: helps prevent disease recurrence in eligible patients. Metastatic breast cancer: provides systemic control of disease progression in postmenopausal women. Neoadjuvant therapy: may be employed to shrink tumors prior to surgery in postmenopausal patients.

Letrozole may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: arthralgia or myalgia. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach. - Headache: occasional throbbing pain. - Insomnia: difficulty sleeping.

Serious or Rare Side Effects: - Severe bone loss: increased risk of osteoporosis and fractures. - Cardiovascular events: rare cases of thromboembolic disease. - Liver function abnormalities: elevated transaminases. - Allergic reactions: rash, angioedema, or anaphylaxis.

When prescribing Letrozole, clinicians should observe several precautionary measures to ensure patient safety.

Assess bone health: evaluate baseline bone mineral density and consider calcium/vitamin D supplementation. Monitor liver function: perform periodic hepatic enzyme tests during therapy. Check cardiovascular risk: review history of thromboembolic disease before initiation. Avoid use in pregnancy: drug is contraindicated in pregnant women (Category X). Drug interactions: review concomitant medications for potential CYP2A6 substrates. Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Letrozole can affect the pharmacokinetics of other medicines; relevant interactions are categorized by clinical significance.

Major Interactions (Avoid): - Strong CYP2A6 inhibitors (e.g., ketoconazole): may increase letrozole plasma levels, raising toxicity risk. - Estrogen‑containing therapies (e.g., hormone replacement): counteract letrozole’s estrogen suppression, reducing efficacy.

Moderate Interactions (Monitor Closely): - Tamoxifen: combined use may alter hormonal balance; monitor patient response. - Anticoagulants (e.g., warfarin): letrozole may enhance anticoagulant effect; check INR regularly. - CYP2A6 inducers (e.g., rifampicin): may lower letrozole concentrations, potentially decreasing effectiveness.